<DOC>
	<DOCNO>NCT01667484</DOCNO>
	<brief_summary>Cognitive impairment , problem think memory , common multiple sclerosis ( MS ) occur independently physical disability . It common reason , along physical fatigue , MS patient stop work . The frequent complaint problem multi-tasking think quickly , correspond impairment cognitive domain processing speed . Currently treatment available prevent relapse physical disability medication show treat cognitive impairment . Amphetamines beneficial selective attention process speed attention deficit hyperactivity disorder ( ADHD ) traumatic brain injury . This study determine whether Adderall XR improve objective measure process speed attention MS patient impair cognitive domain , compare two dos Adderall XR ( 5 10mg ) placebo medication administer . The result study help provide data design large study determine Adderall XR , potentially amphetamine drug , help treat cognitive impairment MS patient .</brief_summary>
	<brief_title>Adderall XR Processing Speed Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Males/Females ≥ 18 year old ≤ 59 year old Relapsing Remitting , Secondary Progressive Primary Progressive MS , per revise McDonald 's Criteria Have receive corticosteroid last thirty day relapse last ninety day An Expanded Disability Status Scale ( EDSS ) ≤ 6.5 If female , must neither pregnant breastfeeding Have evidence medical cause ( ) cognitive impairment Have evidence major depression determine positive Beck Depression IndexFast screen ≥ 13and/or clinician interview evidence severe fatigue Fatigue Severity Scale ≥ 5 . Have demonstrate hypersensitivity amphetamine past Have uncontrolled labile hypertension ( &gt; 135/85 mm Hg , treat untreated ) Have history structural heart disease , include atherosclerosis angina Have diagnosis bipolar disorder history psychotic episode The following medication permit use within 14 day study 1 . Monoamine Oxidase Inhibitors 2 . Sympathomimetics methadone 3 . Antipsychotic agent 4 . Modafinil The following medication permit dose stable ≥ 28 day 1 . Short act benzodiazepine , qhs administration 2 . Anticonvulsants , include gabapentin pregabalin 3 . Bupropion 4 . Tricyclic Antidepressants 5 . Antispasmodics baclofen tizanidine 6 . Anticholinergic medication 7 . Selective serotonin ( norepinephrine ) reuptake inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Cognitive Impairment</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Processing Speed</keyword>
	<keyword>Treatment</keyword>
</DOC>